Therefore, the aim of this study was to examine the potential benefits of human recombinant FGF19 treatment on musculoskeletal parameters and glucose metabolism in a mouse model of CKD which associates muscle wasting, renal osteodystrophy and perturbation of glucose homeostasis18–21. The gene discussed is FGF19; the disease is chronic kidney disease.